# Sparx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sparx

- Industry: Pharmaceuticals
- Headquarters: Yangzhou, China
- Website: www.sparxbio.com
- Total disclosed funding: $30M
- Latest round: Series B (Dec 31, 2021)
- Investors on record: 3

## About

Based in Yangzhou, China, and established in 2021, Sparx is a research-based development-stage biopharmaceutical company that provides immune anti-tumor therapy. The company is a subsidiary of Sparx Group, which incorporated by SparXBiopharmaceutical in US State, SparX Bioscience in England, SparX in Hong Kong, SparX in Jiangsu, and SparX in Shanghai. Sparx Group's R&D center in Chicago, established in 2018. And Sparx Group constructed in house CMP facilities in both Chicago and China to product clinical and commercial drug substance. The company plant in Jiangsu covers 120,000 square meters, including GMP of 40,000 square meters, providing all process of bio-pharmacy from R&D to manufacture.

The company has built a sophisticated multi-specific antibody drug discovery platform and identified 6 IND-ready drug candidates. The SMARTOP™ and LEMMA™ technologies allow the expedite discovery of multi-functional biologics with favorable drug-like properties. An AI-based target identification algorithm feeds a constant stream of novel targets and target counterparts.  Sparx has developed two mouse hybridoma protocols for quick and repetitive immunizations and built a phage display library of 1012 recombinant variants for human antibody discovery. The company develops specific antibodies and antibody drug conjugates, along with CAR-T cell therapy for broader applications of antibodies. In addition, Sparx has developed a new screening technology to expand the clinical applications of small molecular chemical entities as well as several tumor-targeting drug delivery technologies for both small molecule and macromolecule medicines. 

The company plans to build production facilities in Yangzhou, Jiangsu. Moreover, the company will promote process of R&D and manufacturing of 4 product lines.

## Funding rounds

- Series B, Dec 31, 2021, $30M — HighLight Capital, Sangel Capital, Rotating Boulder Fund

## Investors

- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series B
- Rotating Boulder Fund (https://capitalatlas.ai/funds/rotating-boulder-fund) — Series B